Vivek Arora

About Vivek Arora
  • Preclinical assessment of mechanisms of resistance to hormone therapy in prostate cancer has led to the discovery and development of a new medicine, named ARN-509.
  • Dr. Arora has shown that one mechanism of resistance to ARN-509 is the induction of a new hormone receptor, designated Glucocorticoid Receptor (GR).
  • It is believed that GR can, in part, replace the androgen receptor, the engine of prostate cancer progression, causing the patient to become drug resistant.
  • Dr. Arora will test this idea in models of progressive disease and prostate cancer patients, with inhibitors of GR.

What this means to patients: A qualified inhibitor to the glucocorticoid receptor (GR) could be a new treatment for drug-resistant patients with advanced, metastatic prostate cancer.

Award

2013 Millennium: The Takeda Oncology Company

Vivek Arora, MD, PhD

Washington University

Mentor:

Charles Sawyers, MD

Project Title:

Defining strategies to overcome enzalutamide (Xtandi) resistance